Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
Purpose Recent data indicate that extended dosing intervals (EDIs) with lanreotide autogel 120 mg are effective and well-received among patients with acromegaly who have achieved biochemical control with monthly injections of long-acting somatostatin analogues (SSAs). We further evaluated the effect...
Gespeichert in:
| Veröffentlicht in: | Endocrine 2020-12, Vol.70 (3), p.575-583 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 583 |
|---|---|
| container_issue | 3 |
| container_start_page | 575 |
| container_title | Endocrine |
| container_volume | 70 |
| creator | Bernabéu, Ignacio Fajardo, Carmen Marazuela, Mónica Cordido, Fernando Venegas, Eva María de Pablos-Velasco, Pedro Maroto, Gonzalo Piedrola Olvera, María Pilar de Paz, Isabel Pavón Carvalho, Davide Romero, Carme De la Cruz, Guillermo Escolá, Cristina Álvarez |
| description | Purpose
Recent data indicate that extended dosing intervals (EDIs) with lanreotide autogel 120 mg are effective and well-received among patients with acromegaly who have achieved biochemical control with monthly injections of long-acting somatostatin analogues (SSAs). We further evaluated the effectiveness of lanreotide autogel 120 mg delivered at EDIs (>4 weeks) in routine clinical practice.
Methods
Cross-sectional, multicentre, observational study conducted to determine the effectiveness—measured by control of serum insulin-like growth factor 1 (IGF-1)—of lanreotide autogel 120 mg at dosing intervals >4 weeks for ≥6 months in selected patients with acromegaly treated in routine clinical practice (NCT02807233). Secondary assessments included control of growth hormone (GH) levels, treatment adherence, patient satisfaction, and quality of life (QoL) using validated questionnaires (EQ-5D, AcroQoL, and TSQM-9). Patients who received radiotherapy within the last 6 months were excluded.
Results
Among 109 patients evaluated, mean (SD) age was 59.1 (13.2) years. IGF-1 values were normal (mean [SD]: 175.0 [74.5], 95% CI: 160.8 –189.1) in 91.7% of cases and normal in 91.4% of patients without previous radiotherapy treatment (
n
= 81). GH levels were ≤2.5 and ≤1 ng/mL, respectively, in 80.6% and 58.3%. Most patients were treated either every 5–6 (57.8%) or 7–8 weeks (38.5%), with 2.8% treated greater than every 8 weeks. The mean AcroQoL score was 63.0 (20.1). The mean global treatment satisfaction score (TSQM-9) was 75.1 (16.6). Treatment adherence (defined as no missed injections) was 94.5%.
Conclusion
Lanreotide autogel 120 mg at intervals of >4 weeks provided IGF-1 control in more than 90% of patients with acromegaly. Treatment satisfaction and adherence were good. These findings support use of extended dosing intervals in patients who have achieved good biochemical control with long-acting SSAs. |
| doi_str_mv | 10.1007/s12020-020-02424-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7674328</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2428417633</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-43f437688d3548d88f5a35e6d9294d21be1d8ce2efb4652e1d9c1b0ebba272d43</originalsourceid><addsrcrecordid>eNp9UctO3TAQtVBRefUHuqi87CbUz8R3U6lCFCpdiQ1I7CwnHoegxKa2cwWsuu1v8iUY5RaVDYuRPZ4zZzznIPSZkmNKSPMtUUYYqZYQTFSPO2ifSrmqSKl_KHcuZUWIut5DByndEsIYq5uPaI-zhkkhxD66PnUOujxswENKODg8Gh8h5MECNnMOPYy4zHn683fqsckY7jN4CxbbkAbf48FniBszJuxCxKaLYYLejA9HaNeVV_i0PQ_R1c_Ty5Pzan1x9uvkx7rqhKhzJbgTvKmVslwKZZVy0nAJtV2xlbCMtkCt6oCBa0UtWclWHW0JtK0pO1jBD9H3hfdubiewHfgczajv4jCZ-KCDGfTbih9udB82uqkbwZkqBF-3BDH8niFlPQ2pg7HoAGFOuiirBG1qzguULdCyZUoR3OsYSvSLJXqxRC9RLNGPpenL_x98bfnnQQHwBZBKyfcQ9W2Yoy-ivUf7DFTWmmw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2428417633</pqid></control><display><type>article</type><title>Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Bernabéu, Ignacio ; Fajardo, Carmen ; Marazuela, Mónica ; Cordido, Fernando ; Venegas, Eva María ; de Pablos-Velasco, Pedro ; Maroto, Gonzalo Piedrola ; Olvera, María Pilar ; de Paz, Isabel Pavón ; Carvalho, Davide ; Romero, Carme ; De la Cruz, Guillermo ; Escolá, Cristina Álvarez</creator><creatorcontrib>Bernabéu, Ignacio ; Fajardo, Carmen ; Marazuela, Mónica ; Cordido, Fernando ; Venegas, Eva María ; de Pablos-Velasco, Pedro ; Maroto, Gonzalo Piedrola ; Olvera, María Pilar ; de Paz, Isabel Pavón ; Carvalho, Davide ; Romero, Carme ; De la Cruz, Guillermo ; Escolá, Cristina Álvarez</creatorcontrib><description>Purpose
Recent data indicate that extended dosing intervals (EDIs) with lanreotide autogel 120 mg are effective and well-received among patients with acromegaly who have achieved biochemical control with monthly injections of long-acting somatostatin analogues (SSAs). We further evaluated the effectiveness of lanreotide autogel 120 mg delivered at EDIs (>4 weeks) in routine clinical practice.
Methods
Cross-sectional, multicentre, observational study conducted to determine the effectiveness—measured by control of serum insulin-like growth factor 1 (IGF-1)—of lanreotide autogel 120 mg at dosing intervals >4 weeks for ≥6 months in selected patients with acromegaly treated in routine clinical practice (NCT02807233). Secondary assessments included control of growth hormone (GH) levels, treatment adherence, patient satisfaction, and quality of life (QoL) using validated questionnaires (EQ-5D, AcroQoL, and TSQM-9). Patients who received radiotherapy within the last 6 months were excluded.
Results
Among 109 patients evaluated, mean (SD) age was 59.1 (13.2) years. IGF-1 values were normal (mean [SD]: 175.0 [74.5], 95% CI: 160.8 –189.1) in 91.7% of cases and normal in 91.4% of patients without previous radiotherapy treatment (
n
= 81). GH levels were ≤2.5 and ≤1 ng/mL, respectively, in 80.6% and 58.3%. Most patients were treated either every 5–6 (57.8%) or 7–8 weeks (38.5%), with 2.8% treated greater than every 8 weeks. The mean AcroQoL score was 63.0 (20.1). The mean global treatment satisfaction score (TSQM-9) was 75.1 (16.6). Treatment adherence (defined as no missed injections) was 94.5%.
Conclusion
Lanreotide autogel 120 mg at intervals of >4 weeks provided IGF-1 control in more than 90% of patients with acromegaly. Treatment satisfaction and adherence were good. These findings support use of extended dosing intervals in patients who have achieved good biochemical control with long-acting SSAs.</description><identifier>ISSN: 1355-008X</identifier><identifier>EISSN: 1559-0100</identifier><identifier>DOI: 10.1007/s12020-020-02424-z</identifier><identifier>PMID: 32725444</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Acromegaly - drug therapy ; Cross-Sectional Studies ; Delayed-Action Preparations - therapeutic use ; Diabetes ; Endocrinology ; Human Growth Hormone - therapeutic use ; Humanities and Social Sciences ; Humans ; Insulin-Like Growth Factor I ; Internal Medicine ; Medicine ; Medicine & Public Health ; Middle Aged ; multidisciplinary ; Original ; Original Article ; Peptides, Cyclic - therapeutic use ; Quality of Life ; Science ; Somatostatin - analogs & derivatives</subject><ispartof>Endocrine, 2020-12, Vol.70 (3), p.575-583</ispartof><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-43f437688d3548d88f5a35e6d9294d21be1d8ce2efb4652e1d9c1b0ebba272d43</citedby><cites>FETCH-LOGICAL-c446t-43f437688d3548d88f5a35e6d9294d21be1d8ce2efb4652e1d9c1b0ebba272d43</cites><orcidid>0000-0001-8421-7394</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12020-020-02424-z$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12020-020-02424-z$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32725444$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bernabéu, Ignacio</creatorcontrib><creatorcontrib>Fajardo, Carmen</creatorcontrib><creatorcontrib>Marazuela, Mónica</creatorcontrib><creatorcontrib>Cordido, Fernando</creatorcontrib><creatorcontrib>Venegas, Eva María</creatorcontrib><creatorcontrib>de Pablos-Velasco, Pedro</creatorcontrib><creatorcontrib>Maroto, Gonzalo Piedrola</creatorcontrib><creatorcontrib>Olvera, María Pilar</creatorcontrib><creatorcontrib>de Paz, Isabel Pavón</creatorcontrib><creatorcontrib>Carvalho, Davide</creatorcontrib><creatorcontrib>Romero, Carme</creatorcontrib><creatorcontrib>De la Cruz, Guillermo</creatorcontrib><creatorcontrib>Escolá, Cristina Álvarez</creatorcontrib><title>Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly</title><title>Endocrine</title><addtitle>Endocrine</addtitle><addtitle>Endocrine</addtitle><description>Purpose
Recent data indicate that extended dosing intervals (EDIs) with lanreotide autogel 120 mg are effective and well-received among patients with acromegaly who have achieved biochemical control with monthly injections of long-acting somatostatin analogues (SSAs). We further evaluated the effectiveness of lanreotide autogel 120 mg delivered at EDIs (>4 weeks) in routine clinical practice.
Methods
Cross-sectional, multicentre, observational study conducted to determine the effectiveness—measured by control of serum insulin-like growth factor 1 (IGF-1)—of lanreotide autogel 120 mg at dosing intervals >4 weeks for ≥6 months in selected patients with acromegaly treated in routine clinical practice (NCT02807233). Secondary assessments included control of growth hormone (GH) levels, treatment adherence, patient satisfaction, and quality of life (QoL) using validated questionnaires (EQ-5D, AcroQoL, and TSQM-9). Patients who received radiotherapy within the last 6 months were excluded.
Results
Among 109 patients evaluated, mean (SD) age was 59.1 (13.2) years. IGF-1 values were normal (mean [SD]: 175.0 [74.5], 95% CI: 160.8 –189.1) in 91.7% of cases and normal in 91.4% of patients without previous radiotherapy treatment (
n
= 81). GH levels were ≤2.5 and ≤1 ng/mL, respectively, in 80.6% and 58.3%. Most patients were treated either every 5–6 (57.8%) or 7–8 weeks (38.5%), with 2.8% treated greater than every 8 weeks. The mean AcroQoL score was 63.0 (20.1). The mean global treatment satisfaction score (TSQM-9) was 75.1 (16.6). Treatment adherence (defined as no missed injections) was 94.5%.
Conclusion
Lanreotide autogel 120 mg at intervals of >4 weeks provided IGF-1 control in more than 90% of patients with acromegaly. Treatment satisfaction and adherence were good. These findings support use of extended dosing intervals in patients who have achieved good biochemical control with long-acting SSAs.</description><subject>Acromegaly - drug therapy</subject><subject>Cross-Sectional Studies</subject><subject>Delayed-Action Preparations - therapeutic use</subject><subject>Diabetes</subject><subject>Endocrinology</subject><subject>Human Growth Hormone - therapeutic use</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Insulin-Like Growth Factor I</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>multidisciplinary</subject><subject>Original</subject><subject>Original Article</subject><subject>Peptides, Cyclic - therapeutic use</subject><subject>Quality of Life</subject><subject>Science</subject><subject>Somatostatin - analogs & derivatives</subject><issn>1355-008X</issn><issn>1559-0100</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9UctO3TAQtVBRefUHuqi87CbUz8R3U6lCFCpdiQ1I7CwnHoegxKa2cwWsuu1v8iUY5RaVDYuRPZ4zZzznIPSZkmNKSPMtUUYYqZYQTFSPO2ifSrmqSKl_KHcuZUWIut5DByndEsIYq5uPaI-zhkkhxD66PnUOujxswENKODg8Gh8h5MECNnMOPYy4zHn683fqsckY7jN4CxbbkAbf48FniBszJuxCxKaLYYLejA9HaNeVV_i0PQ_R1c_Ty5Pzan1x9uvkx7rqhKhzJbgTvKmVslwKZZVy0nAJtV2xlbCMtkCt6oCBa0UtWclWHW0JtK0pO1jBD9H3hfdubiewHfgczajv4jCZ-KCDGfTbih9udB82uqkbwZkqBF-3BDH8niFlPQ2pg7HoAGFOuiirBG1qzguULdCyZUoR3OsYSvSLJXqxRC9RLNGPpenL_x98bfnnQQHwBZBKyfcQ9W2Yoy-ivUf7DFTWmmw</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Bernabéu, Ignacio</creator><creator>Fajardo, Carmen</creator><creator>Marazuela, Mónica</creator><creator>Cordido, Fernando</creator><creator>Venegas, Eva María</creator><creator>de Pablos-Velasco, Pedro</creator><creator>Maroto, Gonzalo Piedrola</creator><creator>Olvera, María Pilar</creator><creator>de Paz, Isabel Pavón</creator><creator>Carvalho, Davide</creator><creator>Romero, Carme</creator><creator>De la Cruz, Guillermo</creator><creator>Escolá, Cristina Álvarez</creator><general>Springer US</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8421-7394</orcidid></search><sort><creationdate>20201201</creationdate><title>Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly</title><author>Bernabéu, Ignacio ; Fajardo, Carmen ; Marazuela, Mónica ; Cordido, Fernando ; Venegas, Eva María ; de Pablos-Velasco, Pedro ; Maroto, Gonzalo Piedrola ; Olvera, María Pilar ; de Paz, Isabel Pavón ; Carvalho, Davide ; Romero, Carme ; De la Cruz, Guillermo ; Escolá, Cristina Álvarez</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-43f437688d3548d88f5a35e6d9294d21be1d8ce2efb4652e1d9c1b0ebba272d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acromegaly - drug therapy</topic><topic>Cross-Sectional Studies</topic><topic>Delayed-Action Preparations - therapeutic use</topic><topic>Diabetes</topic><topic>Endocrinology</topic><topic>Human Growth Hormone - therapeutic use</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Insulin-Like Growth Factor I</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>multidisciplinary</topic><topic>Original</topic><topic>Original Article</topic><topic>Peptides, Cyclic - therapeutic use</topic><topic>Quality of Life</topic><topic>Science</topic><topic>Somatostatin - analogs & derivatives</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bernabéu, Ignacio</creatorcontrib><creatorcontrib>Fajardo, Carmen</creatorcontrib><creatorcontrib>Marazuela, Mónica</creatorcontrib><creatorcontrib>Cordido, Fernando</creatorcontrib><creatorcontrib>Venegas, Eva María</creatorcontrib><creatorcontrib>de Pablos-Velasco, Pedro</creatorcontrib><creatorcontrib>Maroto, Gonzalo Piedrola</creatorcontrib><creatorcontrib>Olvera, María Pilar</creatorcontrib><creatorcontrib>de Paz, Isabel Pavón</creatorcontrib><creatorcontrib>Carvalho, Davide</creatorcontrib><creatorcontrib>Romero, Carme</creatorcontrib><creatorcontrib>De la Cruz, Guillermo</creatorcontrib><creatorcontrib>Escolá, Cristina Álvarez</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Endocrine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bernabéu, Ignacio</au><au>Fajardo, Carmen</au><au>Marazuela, Mónica</au><au>Cordido, Fernando</au><au>Venegas, Eva María</au><au>de Pablos-Velasco, Pedro</au><au>Maroto, Gonzalo Piedrola</au><au>Olvera, María Pilar</au><au>de Paz, Isabel Pavón</au><au>Carvalho, Davide</au><au>Romero, Carme</au><au>De la Cruz, Guillermo</au><au>Escolá, Cristina Álvarez</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly</atitle><jtitle>Endocrine</jtitle><stitle>Endocrine</stitle><addtitle>Endocrine</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>70</volume><issue>3</issue><spage>575</spage><epage>583</epage><pages>575-583</pages><issn>1355-008X</issn><eissn>1559-0100</eissn><abstract>Purpose
Recent data indicate that extended dosing intervals (EDIs) with lanreotide autogel 120 mg are effective and well-received among patients with acromegaly who have achieved biochemical control with monthly injections of long-acting somatostatin analogues (SSAs). We further evaluated the effectiveness of lanreotide autogel 120 mg delivered at EDIs (>4 weeks) in routine clinical practice.
Methods
Cross-sectional, multicentre, observational study conducted to determine the effectiveness—measured by control of serum insulin-like growth factor 1 (IGF-1)—of lanreotide autogel 120 mg at dosing intervals >4 weeks for ≥6 months in selected patients with acromegaly treated in routine clinical practice (NCT02807233). Secondary assessments included control of growth hormone (GH) levels, treatment adherence, patient satisfaction, and quality of life (QoL) using validated questionnaires (EQ-5D, AcroQoL, and TSQM-9). Patients who received radiotherapy within the last 6 months were excluded.
Results
Among 109 patients evaluated, mean (SD) age was 59.1 (13.2) years. IGF-1 values were normal (mean [SD]: 175.0 [74.5], 95% CI: 160.8 –189.1) in 91.7% of cases and normal in 91.4% of patients without previous radiotherapy treatment (
n
= 81). GH levels were ≤2.5 and ≤1 ng/mL, respectively, in 80.6% and 58.3%. Most patients were treated either every 5–6 (57.8%) or 7–8 weeks (38.5%), with 2.8% treated greater than every 8 weeks. The mean AcroQoL score was 63.0 (20.1). The mean global treatment satisfaction score (TSQM-9) was 75.1 (16.6). Treatment adherence (defined as no missed injections) was 94.5%.
Conclusion
Lanreotide autogel 120 mg at intervals of >4 weeks provided IGF-1 control in more than 90% of patients with acromegaly. Treatment satisfaction and adherence were good. These findings support use of extended dosing intervals in patients who have achieved good biochemical control with long-acting SSAs.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>32725444</pmid><doi>10.1007/s12020-020-02424-z</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-8421-7394</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1355-008X |
| ispartof | Endocrine, 2020-12, Vol.70 (3), p.575-583 |
| issn | 1355-008X 1559-0100 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7674328 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Acromegaly - drug therapy Cross-Sectional Studies Delayed-Action Preparations - therapeutic use Diabetes Endocrinology Human Growth Hormone - therapeutic use Humanities and Social Sciences Humans Insulin-Like Growth Factor I Internal Medicine Medicine Medicine & Public Health Middle Aged multidisciplinary Original Original Article Peptides, Cyclic - therapeutic use Quality of Life Science Somatostatin - analogs & derivatives |
| title | Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T14%3A38%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20lanreotide%20autogel%20120%E2%80%89mg%20at%20extended%20dosing%20intervals%20for%20acromegaly&rft.jtitle=Endocrine&rft.au=Bernab%C3%A9u,%20Ignacio&rft.date=2020-12-01&rft.volume=70&rft.issue=3&rft.spage=575&rft.epage=583&rft.pages=575-583&rft.issn=1355-008X&rft.eissn=1559-0100&rft_id=info:doi/10.1007/s12020-020-02424-z&rft_dat=%3Cproquest_pubme%3E2428417633%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2428417633&rft_id=info:pmid/32725444&rfr_iscdi=true |